Across TCGA pan-cancer cohorts, KRT18P65 RNA differs between tumor and matched normal tissue in 12 of 18 cancer types tested, making tumor–normal expression one of KRT18P65’s most consistent transcriptional readouts.
The strongest signal is observed in lung adenocarcinoma (LUAD), where KRT18P65 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types KRT18P65 is over-expressed in tumor.
LUAD, STAD, and COAD are the cancer types where KRT18P65 tumor–normal differential expression is most reproducible.
RNA tumor vs normal associations by lineage
Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in KRT18P65 RNA (log2); positive values indicate higher expression in tumor. p-values are from the differential-expression test.